MedWatch

Novo drug ziltivekimab meets primary endpoint in inflammatory biomarker trial

According to Novo Nordisk, the trial showed a significant reduction in several inflammatory biomarkers associated with atherosclerosis in people with advanced chronic kidney disease.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has released the results of its phase II trial of ziltivekimab, 'Rescue'. The drug, which is taken monthly, attained its primary goal of reducing inflammatory biomarkers associated with atherosclerosis (hardened arteries, -ed.) in people with advanced chronic kidney disease.

The press release written by Novo Nordisk states that the data was released at the American College of Cardiology's 70th annual conference (this year, a virtual conference) and published in the Lancet.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs